Osteoporosis Market Set to Expand Significantly During the Forecast Period (2025-2034) Due to Rising Aging Population and Novel Therapeutics | DelveInsight

The osteoporosis market is expanding steadily, driven largely by aging populations and rising awareness of fracture risk and bone health. Advances in diagnostics and novel therapies, including EB613 (EnteraBio), AGA2118 (Angitia Biopharmaceuticals), RT-102 (Rani Therapeutics), and others, are widening treatment options and boosting market value.

LAS VEGAS, Nov. 18, 2025 /PRNewswire/ -- DelveInsight's Osteoporosis Market Insights report includes a comprehensive understanding of current treatment practices, osteoporosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan). 

Osteoporosis Market Summary

• The market size for osteoporosis in the leading markets is expected to grow significantly by 2034.
• The United States accounted for the highest osteoporosis treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
• In the US, more than 53 million people either already have osteoporosis or are at high risk due to low bone mass.
• Leading osteoporosis companies developing emerging therapies, such as EnteraBio, Angitia Biopharmaceuticals, Rani Therapeutics, and others, are developing new therapy for osteoporosis that can be available in the osteoporosis market in the coming years. 
• The promising osteoporosis therapies in clinical trials include EB613, AGA2118, RT-102, and others.

Discover the osteoporosis new treatment @ New Treatments for Osteoporosis

Key Factors Driving the Growth of the Osteoporosis Market 

Rising Prevalence of Osteoporosis

The global burden of osteoporosis is increasing rapidly due to the growing elderly population, especially among postmenopausal women. As life expectancy rises, the prevalence of age-related bone loss and fragility fractures continues to drive the demand for osteoporosis diagnosis and treatment.

Growing Awareness and Screening Programs

Public health initiatives and awareness campaigns emphasizing bone health, fracture prevention, and early diagnosis are increasing treatment rates. Healthcare organizations and patient advocacy groups are actively promoting screening for postmenopausal and elderly populations.

Emergence of Novel Classes in Osteoporosis Management

A robust range of treatments, including bisphosphonates, SERMs, anabolic agents, and RANKL inhibitors, provides personalized approaches.

Launch of Emerging Osteoporosis Drugs

The expected launch of emerging therapies such as EB613 (EnteraBio), AGA2118 (Angitia Biopharmaceuticals), RT-102 (Rani Therapeutics), and others will change the dynamics of the osteoporosis market in the coming years.

Emergence of Oral Anabolic Therapies in Osteoporosis Management

The emergence of oral anabolic therapies, such as EB613, addresses the accessibility and compliance limitations of subcutaneous injectables, offering improved adherence, convenience, and clinical adoption in osteoporosis management.

Romosozumab Paves the Way for Next-Generation Osteoporosis Therapies

Agents like romosozumab (EVENITY), which have both anabolic and antiresorptive effects, open new avenues for faster and more robust improvements in bone density, especially in patients at high risk of fractures.

Osteoporosis Market Analysis

The osteoporosis treatment landscape is primarily dominated by pharmacological interventions, broadly categorized into anti-resorptive agents (such as bisphosphonates, estrogen agonists/antagonists, estrogens, calcitonin, and denosumab), anabolic agents (including teriparatide and abaloparatide), and mixed agents like romosozumab. Beyond these established therapies, additional anti-resorptive options include estrogen replacement and selective estrogen receptor modulators (SERMs), notably raloxifene, lasofoxifene, and bazedoxifene. Dietary supplements, such as calcium and vitamin D, also contribute to supportive benefits for patients with osteoporosis.

In October 2019, the U.S. FDA approved BONSITY, a biosimilar of FORTEO, for the treatment of osteoporosis in patients at high risk of fractures. When conservative approaches, such as medication, exercise, and diet, fail to produce results within three months, surgical interventions become necessary. Two minimally invasive options for spinal osteoporotic fractures include kyphoplasty and vertebroplasty.

Currently, the osteoporosis market is largely driven by biosimilars and generics, which continue to show strong therapeutic promise. The pipeline, however, remains relatively limited, with only a few investigational products under development by companies such as EnteraBio, Angitia, and Rani Therapeutics. OssiFi is actively seeking collaborative partnerships with organizations aligned with its mission to address disorders linked to the sclerostin pathway, including osteoporosis. Notably, EB613 represents a novel approach in this space, as the first oral, osteoanabolic (bone-building) tablet designed for once-daily use, offering a potential dual mechanism of action to bridge current treatment gaps.

To know more about osteoporosis treatment options, visit @ Approved Osteoporosis Drugs

Osteoporosis Competitive Landscape

The potential osteoporosis drugs in clinical trials include EB613 (EnteraBio), AGA2118 (Angitia Biopharmaceuticals), RT-102 (Rani Therapeutics), and others.

EnteraBio's EB613 is being developed as the first oral, once-daily osteoanabolic tablet aimed at postmenopausal women with low bone mineral density (BMD) and high-risk osteoporosis who have not experienced prior fractures. In a placebo-controlled, dose-ranging Phase II trial, EB613 achieved both its primary and secondary endpoints. The planned Phase III registrational trial for EB613 is structured to meet the quantitative BMD benchmarks proposed by SABRE and is expected to commence in the second half of 2025. Following FDA Type C and D meetings, the company received alignment on the use of a placebo, the defined patient population, and BMD as a key endpoint. A BMD Endpoint Qualification Ruling and a SABRE update are anticipated in 2025.

Rani Therapeutics' RT-102 represents the original RaniPill capsule formulation containing the parathyroid hormone analog PTH(1-34), designed to treat osteoporosis. Rani Therapeutics has completed a pre-Investigational New Drug (IND) meeting with the FDA for RT-102, which utilizes the RaniPill GO platform and a proprietary human PTH(1-34) analog formulation. The company anticipates initiating a Phase II clinical trial for RT-102.

Angitia Biopharmaceuticals' AGA2118 is a bispecific antibody under development for osteoporosis that simultaneously targets sclerostin and DKK1, two key inhibitors of WNT signaling in osteoblasts and bone metabolism. By neutralizing both molecules, AGA2118 is intended to prevent compensatory upregulation of either target, thereby enhancing BMD improvements in osteoporotic patients. Angitia, which fully owns the bispecific antibody, announced in November 2024 the first patient dosing in ARTEMIS, its Phase II clinical study evaluating AGA2118 for osteoporosis.

The anticipated launch of these emerging therapies are poised to transform the osteoporosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the osteoporosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about therapy for osteoporosis @ Osteoporosis Clinical Trials 

Recent Developments in the Osteoporosis Market

• In September 2025, Entera Bio announced that data from its lead program, EB613, currently in late-stage clinical development for postmenopausal women with osteoporosis, had been selected for presentation at the American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting in Seattle, Washington.
• In September 2025, Shanghai Henlius Biotech and Organon announced that the US Food and Drug Administration (FDA) had approved BILDYOS (denosumab-nxxp) injection 60 mg/mL and BILPREVDA (denosumab-nxxp) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.

What is Osteoporosis?

Osteoporosis is a chronic bone disease characterized by a decrease in bone mass and deterioration of bone tissue, leading to increased fragility and a higher risk of fractures. It occurs when the balance between bone formation and bone resorption is disrupted; bones lose minerals such as calcium faster than they are replaced, making them weak and porous. Often referred to as the "silent disease," osteoporosis typically progresses without noticeable symptoms until a fracture occurs, most commonly in the hip, spine, or wrist. It primarily affects postmenopausal women due to hormonal changes, but can also impact men and individuals with certain medical conditions or lifestyle factors. Early diagnosis and preventive measures, including adequate calcium and vitamin D intake, regular exercise, and medication when necessary, are crucial for maintaining bone health and reducing fracture risk.

Osteoporosis Epidemiology Segmentation

The osteoporosis epidemiology section provides insights into the historical and current osteoporosis patient pool and forecasted trends for the leading markets. Osteoporosis affects over 3 million people in the UK, with more than 500,000 people receiving hospital treatment for fragility fractures every year as a result of osteoporosis.

The osteoporosis market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

• Prevalence of Osteoporosis
• Diagnosed Prevalence of Osteoporosis
• Gender-specific Prevalence of Osteoporosis
• Prevalence of Primary Osteoporosis
• Prevalence of Secondary Osteoporosis
• Incidence of Osteoporotic Fractures
• Osteoporosis-related Comorbidities

Scope of the Osteoporosis  Market Report

• Therapeutic Assessment: Osteoporosis current marketed and emerging therapies
• Osteoporosis Market Dynamics: Key Market Forecast Assumptions of Emerging Osteoporosis Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Osteoporosis Market Access and Reimbursement

Download the report to understand which factors are driving osteoporosis therapeutics market trends @ Osteoporosis Market Trends

Table of Contents

Related Reports

Osteoporosis Clinical Trial Analysis

Osteoporosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key osteoporosis companies, including mAbxience, Alvotech, Transcenta Holding, Suzhou Suncadia Biopharmaceuticals, GlycoNex, Cellatoz Therapeutics, Enzo Biochem, Surrozen, among others.

Post-Menopausal Osteoporosis Market

Post-Menopausal  Osteoporosis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key post-menopausal osteoporosis companies including Teva Pharmaceutical, Eli Lilly and Company, HEXAL, Celltrion, among others.

Post-Menopausal Osteoporosis Clinical Trial Analysis

Post-Menopausal Osteoporosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key post-menopausal osteoporosis companies, including Teva Pharmaceutical, Eli Lilly and Company, HEXAL, Celltrion, among others.

Osteoarthritis Market

Osteoarthritis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key osteoarthritis companies including Paradigm Biopharma, Organogenesis, Amzell, Sorrento Therapeutics, Kolon TissueGene, Juniper Biologics, Biosplice Therapeutics, AKL Research and Development, BioSenic (Bone Therapeutics), Xalud Therapeutics, Eli Lilly and Company, Grünenthal, Techfields Pharma, Taiwan Liposome Company, UnicoCell Biomed, Medipost, Moebius Medical, Propella Therapeutics, Vizuri Health Sciences, Medivir, Novartis, BioSolution, Centrexion Therapeutics, Levicept, Merck KGaA, TrialSpark, Novo Nordisk, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur  
info@delveinsight.com
+14699457679
www.delveinsight.com  

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg